Table 1.
Vaccines discussed in this review.
| Type | Manufacturer | Name | Stabilizing mutations | Virus strain | Eukaryotic production cell line | Dosage | References |
|---|---|---|---|---|---|---|---|
| mRNA | BioNTech-Pfizer (Germany, USA) | BNT162b2, Comirnaty | Yes (prolines) | Wuhan-Hu-1 | not applicable | 30 µg RNA (2x) | 44,46 |
| mRNA | Moderna-NIAID (USA) | mRNA-1273, COVID-19 Vaccine Moderna | yes (prolines) | Wuhan-Hu-1 | not applicable | 100 µg RNA (2x) | 45,47 |
| mRNA | CureVac (Germany) | CVnCoV | yes (prolines) | Wuhan-Hu-1 | not applicable | 12 µg RNA (2x) | 56 |
| Adenovector | University of Oxford-AstraZeneca (UK, Sweden) | COVID-19 vaccine AstraZeneca, AZD1222, ChAdOx1-S, Vaxzeria; Covishield | no | Wuhan-Hu-1 | HEK293 | 5×1010 adenovirus vector particles (2x) | 65,66 |
| Adenovector | CanSino Biological Inc., Beijing Institute of Biotechnology (China) | Ad5 nCoV, Convidecia | no | Wuhan-Hu-1 | HEK293 | 5×1010 adenovirus vector particles (2x) | 61 |
| Adenovector | Gamaleya Research Institute (Russia) | rAd26-S + rAd5-S, Gam-COVID-Vac, Sputnik V | no | Wuhan-Hu-1 (probably) | HEK293 | 10×1010 adenovirus vector particles (2x) | 67,68 |
| Adenovector | Janssen-Johnson & Johnson (NL/USA) | Ad26.COV2.S, COVID-19 Vaccine Janssen | yes (prolines, furin cleavage site) | Wuhan-Hu-1 | PER.C6 | 5×1010 adenovirus vector particles (1x) | 19,62,63 |
| Inactivated whole virus | Sinopharm,Beijing Institute of Biological Products Co (China) | BBIBP-CorV, Sinopharm COVID-19 vaccine | not applicable | Wuhan-Hu-1-like HB02 strain | Vero | 4 µg proposed (2x) | 89,90 |
| Inactivated whole virus | Sinovac (China) | CoronaVac | not applicable | Wuhan-Hu-1-like CN2 strain | Vero | 3 µg proposed (2x) | 86,87 |
| Inactivated whole virus | Bharat Biotech (India) | Covaxin, BBV152 | not applicable | NIV2020-770 (D614G) | Vero | 6 µg proposed (2x) | 97,141,142 |
| Subunit | Novavax (USA) | NVX-CoV2373 | yes (prolines, furin cleavage site) | Wuhan-Hu-1 | Sf9 | 5 µg S ( +50 µg adjuvant) (2x) | 98,99 |